Q2 2019 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$215M+7.2% YoY

Gross Profit

$165M76.5% margin

Operating Income

-$6M-2.6% margin

Net Income

-$4M-1.9% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

-0.6%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$30M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$474M

Stockholders' Equity

$1.1B

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$215M	$201M	+7.2%
Gross Profit	$165M	$155M	+6.2%
Operating Income	-$6M	$16M	-135.2%
Net Income	-$4M	$13M	-132.1%

Revenue Segments

Molecular Diagnostic Testing

$197M48%

Molecular Diagnostic Hereditary Cancer Testing

$119M29%

Molecular Diagnostic Genesight Testing

$30M7%

Molecular Diagnostic Prenatal Testing

$25M6%

Pharmaceutical And Clinical Services

$19M4%

Molecular Diagnostic Vectra Testing

$12M3%

Molecular Diagnostic Prolaris Testing

$6M2%

Molecular Diagnostic Endo Predict Testing

$3M1%

Molecular Diagnostic Other Testing

$2M0%